Top 10 Cell & Gene Therapy Events of 2016

Ed FieldPresident, Spine/Disc Division, BioRestorative Therapies@EdLField

#10

AMAG Pharma buys Cord Blood Registry for $700M

#10

Suspension/restart of Juno Therapeutics P2 CAR-T trial

#10

AMAG Pharma buys Cord Blood Registry for $700M

#9

MACI Approval

#10

AMAG Pharma buys Cord Blood Registry for $700M

#8

Tigenix Deal with Takeda

#10

AMAG Pharma buys Cord Blood Registry for $700M

#7

MULTIPLE $500M+ Acquisitions- Allergan Buys LifeCell for $2.9B

- Pfizer buys Bamboo for $695M

#10

AMAG Pharma buys Cord Blood Registry for $700M

#6

Mesoblast Signs Deal with Malinkrodt – after losing

partnership with Teva

#10

AMAG Pharma buys Cord Blood Registry for $700M

#5

Bayer Teams with Versant to Form BlueRock

#10

AMAG Pharma buys Cord Blood Registry for $700M

#4

Positive Novartis ELIANA Trial Data

#10

AMAG Pharma buys Cord Blood Registry for $700M

#3

Kite Pharma Files First BLA for CAR-T Therapy

#10

AMAG Pharma buys Cord Blood Registry for $700M

#2

MULTIPLE $Billion DealsBaxalta/Precision, BlueBird/Medigene,

Biogen/Penn

#10

AMAG Pharma buys Cord Blood Registry for $700M

#1

Approval of Strimvelis, first ex vivo gene therapy product in

Europe for treating SCID